IRTC:NSD-iRhythm Technologies Inc. (USD)

EQUITY | Medical Devices | NASDAQ Global Market

Last Closing

USD 88.66

Change

-1.73 (-1.91)%

Market Cap

USD 0.62B

Volume

0.23M

Analyst Target

USD 222.50
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

iRhythm Technologies Inc is a commercial-stage digital healthcare company redefining the way cardiac arrhythmias are clinically diagnosed by combining wearable biosensing technology with cloud-based data analytics and machine-learning capabilities.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-23 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
DXCM DexCom Inc

-0.50 (-0.62%)

USD 30.74B
PODD Insulet Corporation

-3.24 (-1.22%)

USD 19.01B
MASI Masimo Corporation

-2.01 (-1.19%)

USD 9.43B
BRKR Bruker Corporation

+0.39 (+0.68%)

USD 9.04B
PRCT Procept Biorobotics Corp

-0.02 (-0.02%)

USD 4.83B
NVCR Novocure Ltd

-0.31 (-1.01%)

USD 3.61B
NARI Inari Medical Inc

-2.21 (-3.99%)

USD 3.25B
LIVN LivaNova PLC

-0.60 (-1.26%)

USD 2.83B
QDEL Quidel Corporation

-0.18 (-0.40%)

USD 2.57B
TMDX TransMedics Group Inc

+0.95 (+1.54%)

USD 2.07B

ETFs Containing IRTC

FDHT:XETRA Fidelity Digital Health U.. 2.58 % 0.00 %

+0.10 (+2.06%)

N/A
XHE SPDR® S&P Health Care Eq.. 2.07 % 0.35 %

-0.26 (2.06%)

USD 0.21B
SLIM 0.00 % 0.50 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -17.17% 59% D- 35% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -17.17% 59% D- 34% F
Trailing 12 Months  
Capital Gain -17.20% 59% D- 34% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -17.20% 59% D- 34% F
Trailing 5 Years  
Capital Gain 30.38% 86% B+ 68% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 30.38% 86% B+ 64% D
Average Annual (5 Year Horizon)  
Capital Gain 8.90% 52% F 59% D-
Dividend Return 8.90% 52% F 57% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 71.15% 48% F 28% F
Risk Adjusted Return 12.51% 54% F 44% F
Market Capitalization 0.62B 92% A 82% B

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Devices) Ratio vs. Market (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A
Price/Book Ratio 37.15 4% 4%
Price / Cash Flow Ratio -53.21 95% 95%
Price/Free Cash Flow Ratio -34.37 96% 95%
Management Effectiveness  
Return on Equity -103.34% 39% 20%
Return on Invested Capital -48.45% 39% 24%
Return on Assets -8.93% 68% 36%
Debt to Equity Ratio 16.64% 63% 64%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector